Menu Search
Equities

Perimeter Medical Imaging AI Inc

4PC:FRA

Perimeter Medical Imaging AI Inc

Actions
  • Price (EUR)0.346
  • Today's Change0.042 / 13.82%
  • Shares traded12.00
  • 1 Year change-73.59%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 07:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Perimeter Medical Imaging AI, Inc. is a medical technology company driven to transform cancer surgery with resolution, real-time, imaging tools to address high unmet medical needs. It develops and commercializes in-procedural medical imaging tools. The Company’s Perimeter Optical Coherence Tomography (OCT) system, which provides cross-sectional, real-time margin visualization of tissue microstructures during surgical procedures. The Perimeter S-Series OCT is designed to provide surgeons with the clinical support they need in the OR. The OCT medical imaging system includes an intraoperative device for automated scanning of a tissue specimen that provides a rapid subsurface map of up to a 10 cm by 10 cm surface area; a specimen-handling consumable designed to hold and maintain orientation of the specimen, and an image library and training set. Its machine learning tools and artificial intelligence technology, called ImgAssist AI, through clinical development under its ATLAS AI project.

  • Revenue in CAD (TTM)403.54k
  • Net income in CAD-14.04m
  • Incorporated2020
  • Employees--
  • Location
    Perimeter Medical Imaging AI Inc8585 N. Stemmons Fwy., Suite 106NDALLAS 75247United StatesUSA
  • Phone+1 (214) 845-5154
  • Websitehttps://ir.perimetermed.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.